These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 33815976)

  • 1. Endothelial Dysfunction and Atherosclerosis in Patients With Autosomal Dominant Polycystic Kidney Disease.
    Ekinci İ; Buyukkaba M; Cinar A; Tunc M; Cebeci E; Gursu M; Kazancioglu R
    Cureus; 2021 Feb; 13(2):e13561. PubMed ID: 33815976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of endothelial dysfunction in patients with familial Mediterranean fever: the relationship between the levels of asymmetric dimethylarginine and endocan with carotid intima-media thickness and endothelium-dependent vasodilation.
    Ozalper V; Kara M; Tanoglu A; Cetındaglı I; Ozturker C; Hancerlı Y; Hıra S; Kara K; Beyazıt Y; Yazgan Y
    Clin Rheumatol; 2017 Sep; 36(9):2071-2077. PubMed ID: 28074304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effect of Smoking on Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease Patients with Preserved Renal Function.
    Gul CB; Yildiz A; Sag S; Oruc A; Ersoy A; Gullulu S
    Ren Fail; 2021 Dec; 43(1):1124-1129. PubMed ID: 34256663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levels of Endocan, Angiopoietin-2, and Hypoxia-Inducible Factor-1a in Patients with Autosomal Dominant Polycystic Kidney Disease and Different Levels of Renal Function.
    Raptis V; Bakogiannis C; Loutradis C; Boutou AK; Lampropoulou I; Intzevidou E; Sioulis A; Balaskas E; Sarafidis PA
    Am J Nephrol; 2018; 47(4):231-238. PubMed ID: 29597186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exercise capacity in polycystic kidney disease.
    Reinecke NL; Cunha TM; Heilberg IP; Higa EM; Nishiura JL; Neder JA; Almeida WS; Schor N
    Am J Kidney Dis; 2014 Aug; 64(2):239-46. PubMed ID: 24787761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum Copeptin, NLPR3, and suPAR Levels among Patients with Autosomal-Dominant Polycystic Kidney Disease with and without Impaired Renal Function.
    Raptis V; Loutradis C; Boutou AK; Faitatzidou D; Sioulis A; Ferro CJ; Papagianni A; Sarafidis PA
    Cardiorenal Med; 2020; 10(6):440-451. PubMed ID: 33202410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperaldosteronism and cardiovascular risk in patients with autosomal dominant polycystic kidney disease.
    Lai S; Petramala L; Mastroluca D; Petraglia E; Di Gaeta A; Indino E; Panebianco V; Ciccariello M; Shahabadi HH; Galani A; Letizia C; D'Angelo AR
    Medicine (Baltimore); 2016 Jul; 95(29):e4175. PubMed ID: 27442639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early atherosclerosis in normotensive patients with autosomal dominant polycystic kidney disease: the relation between epicardial adipose tissue thickness and carotid intima-media thickness.
    Sag S; Yildiz A; Gullulu S; Gungoren F; Ozdemir B; Cegilli E; Oruc A; Ersoy A; Gullulu M
    Springerplus; 2016; 5():211. PubMed ID: 27026905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum uric acid levels and endothelial dysfunction in patients with autosomal dominant polycystic kidney disease.
    Kocyigit I; Yilmaz MI; Orscelik O; Sipahioglu MH; Unal A; Eroglu E; Kalay N; Tokgoz B; Axelsson J; Oymak O
    Nephron Clin Pract; 2013; 123(3-4):157-64. PubMed ID: 23887359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endocan, TGF-beta, and ADMA as Risk Factors for Endothelial Dysfunction and Possible Vascular Disease in Patients with Subclinical Hypothyroidism.
    Arpaci D; Karakece E; Tocoglu AG; Ergenc H; Gurol G; Ciftci IH; Tamer A
    Ann Clin Lab Sci; 2016 Dec; 46(6):601-607. PubMed ID: 27993872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood pressure response to exercise in unaffected relatives of autosomal dominant polycystic kidney disease patients: an observational study.
    Yenigun EC; Turgut D; Cevher SK; Yucel C; Aypak C; Dede F
    Int Urol Nephrol; 2023 Sep; 55(9):2313-2319. PubMed ID: 36872421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutrophil-to-lymphocyte ratio, insulin resistance, and endothelial dysfunction in patients with autosomal dominant polycystic kidney disease.
    Turkmen K; Tufan F; Selçuk E; Akpınar T; Oflaz H; Ecder T
    Indian J Nephrol; 2013 Jan; 23(1):34-40. PubMed ID: 23580803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel markers of endothelial dysfunction and inflammation in Behçet's disease patients with ocular involvement: epicardial fat thickness, carotid intima media thickness, serum ADMA level, and neutrophil-to-lymphocyte ratio.
    Yuksel M; Yildiz A; Oylumlu M; Turkcu FM; Bilik MZ; Ekinci A; Elbey B; Tekbas E; Alan S
    Clin Rheumatol; 2016 Mar; 35(3):701-8. PubMed ID: 25744156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum Fas Ligand, Serum Myostatin and Urine TGF-β1 Are Elevated in Autosomal Dominant Polycystic Kidney Disease Patients with Impaired and Preserved Renal Function.
    Raptis V; Bakogiannis C; Loutradis C; Boutou AK; Sioulis A; Balaskas E; Zebekakis P; Sarafidis PA
    Kidney Blood Press Res; 2018; 43(3):744-754. PubMed ID: 29794429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endothelial dysfunction and increased carotid intima-media thickness in patients with autosomal dominant polycystic kidney disease.
    Kocaman O; Oflaz H; Yekeler E; Dursun M; Erdogan D; Demirel S; Alisir S; Turgut F; Mercanoglu F; Ecder T
    Am J Kidney Dis; 2004 May; 43(5):854-60. PubMed ID: 15112176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum endocan levels, carotid intima-media thickness and microalbuminuria in patients with newly diagnosed hypertension.
    Oktar SF; Guney I; Eren SA; Oktar L; Kosar K; Buyukterzi Z; Alkan E; Biyik Z; Erdem SS
    Clin Exp Hypertens; 2019; 41(8):787-794. PubMed ID: 31390906
    [No Abstract]   [Full Text] [Related]  

  • 17. α-lipoic acid in patients with autosomal dominant polycystic kidney disease.
    Lai S; Petramala L; Muscaritoli M; Cianci R; Mazzaferro S; Mitterhofer AP; Pasquali M; D'Ambrosio V; Carta M; Ansuini M; Ramaccini C; Galani A; Amabile MI; Molfino A; Letizia C
    Nutrition; 2020 Mar; 71():110594. PubMed ID: 31790890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uroflowmetry alterations in patients with autosomal dominant polycystic kidney disease.
    Lai S; Mittherhofer AP; Cianci R; Riviello L; Vocaturi M; Mastroluca D; Ciccariello M; Von Heland M; Ricciuti GP; Salciccia S; Mazzaferro S
    Eur Rev Med Pharmacol Sci; 2019 Apr; 23(7):2734-2743. PubMed ID: 31002123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subclinic arterial and left ventricular systolic impairment in autosomal dominant polycystic kidney disease with preserved renal functions.
    Akpinar TS; Kucukdagli P; Ozer PK; Karaayvaz EB; Ince B; Bakkaloglu OK; Sarihan I; Medetalibeyoglu A; Altinkaynak M; Uzun DD; Bozbora E; Kose M; Ecder T; Yazici H
    Int J Cardiovasc Imaging; 2022 Feb; 38(2):271-278. PubMed ID: 34436702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum endocan and endothelial dysfunction in childhood acute lymphoblastic leukemia survivors: a tertiary center experience.
    Sherief LM; Abd El-Khalek ER; Libda IA; Gaber OA; Kamal NM; Soliman BK; Mokhtar WA; Mokhtar GA; Salah HE; Kamar GM; Zakaria M
    Ther Adv Chronic Dis; 2021; 12():20406223211015963. PubMed ID: 34104378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.